Protocol Ledger

NCT06360094 · Phase II · TERMINATED

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Interventional Phase II clinical trial protocol NCT06360094 sponsored by Boehringer Ingelheim in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-28 Enrollment: 85 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06360094
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)85 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06360094
Protocol FieldVerified Registry Value
NCT IdentifierNCT06360094
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment85 participants (ACTUAL)
Registered Start Date2024-08-28
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI